Alves H C, Valentim A M, Olsson I A S, Antunes L M
CECAV-UTAD, Centro de Estudos de Ciências Animais e Veterinárias, Universidade de Trás-os-Montes e Alto Douro, Vila Real, Portugal.
Lab Anim. 2007 Jul;41(3):329-36. doi: 10.1258/002367707781282767.
The combination of propofol and a rapid-acting opioid, such as fentanyl, sufentanil or remifentanil, is a relatively safe, total intravenous anaesthesia technique, commonly used in humans and which has been investigated in laboratory animals. The objective of this study was to evaluate these combinations for anaesthesia of mice by the intraperitoneal (i.p.) route. Sixty-seven mice, divided into groups of four, were used to test 28 combinations of propofol alone and propofol with fentanyl, sufentanil or remifentanil administered i.p. The dose ranges of drugs studied were propofol 50-200 mg/kg, fentanyl 0.2-0.4 mg/kg, sufentanil 0.05-0.1 mg/kg and remifentanil 0.2-1.0 mg/kg. The loss of righting reflex (RR) and the loss of pedal withdrawal reflex (PWR) were recorded along with the duration and quality of recovery. The results obtained in these studies were unpredictable. The same dose combinations of propofol and opioids were associated with different responses in different individuals. Higher doses did not induce loss of RR and PWR in all animals and were associated with high mortality rates. An adequate hypnotic level was only observed with higher doses of propofol. The synergistic effect of propofol and the opioids was not sufficient to allow surgical procedures. Animals that reached PWR loss showed tail rigidity, shaking limbs and scratched their heads with their forefeet. Higher opioid doses induced respiratory depression and higher death rates. The inconsistency between and within groups may be associated with the i.p. route. The results reported here show that the i.p. route is not appropriate for mouse anaesthesia using propofol alone or in combination with fentanyl, sufentanil or remifentanil.
丙泊酚与速效阿片类药物(如芬太尼、舒芬太尼或瑞芬太尼)联合使用,是一种相对安全的全静脉麻醉技术,常用于人类,也已在实验动物中进行研究。本研究的目的是评估这些组合通过腹腔内(i.p.)途径对小鼠进行麻醉的效果。将67只小鼠分成每组4只,用于测试单独使用丙泊酚以及丙泊酚与芬太尼、舒芬太尼或瑞芬太尼腹腔内给药的28种组合。所研究药物的剂量范围为:丙泊酚50 - 200 mg/kg、芬太尼0.2 - 0.4 mg/kg、舒芬太尼0.05 - 0.1 mg/kg和瑞芬太尼0.2 - 1.0 mg/kg。记录翻正反射(RR)消失和足趾退缩反射(PWR)消失情况以及恢复的持续时间和质量。这些研究中获得的结果不可预测。相同剂量组合的丙泊酚和阿片类药物在不同个体中产生不同反应。较高剂量并非在所有动物中都能诱导RR和PWR消失,且与高死亡率相关。仅在使用较高剂量丙泊酚时才观察到足够的催眠水平。丙泊酚和阿片类药物的协同作用不足以允许进行外科手术。达到PWR消失的动物表现出尾巴僵硬、肢体抖动并用前爪挠头。较高的阿片类药物剂量会导致呼吸抑制和更高的死亡率。组间和组内的不一致可能与腹腔内途径有关。此处报告的结果表明,腹腔内途径不适用于单独使用丙泊酚或与芬太尼、舒芬太尼或瑞芬太尼联合对小鼠进行麻醉。